Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selumetinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 0.94 |
| ▸ | MAP2K2 known ✓ | P36507 | 2/20 | 0.94 |
| ▸ | SMC2 | O95347 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.94 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.94 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.94 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.94 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | NQO2 | P16083 | 1/20 | 0.79 |
| ▸ | BRAF | P15056 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selumetinib SCHEMBL29744701 | 1.00 | MAP2K1 (0.94) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29353582 | 0.97 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL155456 | 0.97 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29555068 | 0.97 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546029 | 0.92 | MAP2K1 (0.91) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL30487255 | 0.91 | MAP2K1 (0.89) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546033 | 0.91 | MAP2K1 (0.82) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL1038067 | 0.90 | MAP2K1 (0.85) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL30487260 | 0.90 | MAP2K1 (0.88) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL21501424 | 0.90 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12552751-B2 | Crystal forms A, B, C, D, E, F and G of selumetinib sulfate and preparation methods thereof | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD. (TW) | 2026-02-17 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025097041-A1 | METHODS FOR THE DETECTION AND TREATMENT OF RESISTANT CANCERS CO-EXPRESSING ALPP AND/OR ALPG/ALPPL2 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-08 | — | — | WO | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-20240400519-A1 | CRYSTAL FORMS A, B, C, D, E, F AND G OF SELUMETINIB SULFATE AND PREPARATION METHODS THEREOF | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD. (TW) | 2024-12-05 | — | — | US | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118103340-A | Method for manufacturing medical injection device and medical injection device manufactured by same | 斯特瓦纳托集团有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2024-04-11 | — | — | US | claimed |
| WO-2024003942-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SELUMETINIB SULFATE | NATCO PHARMA LIMITED (IN) | 2024-01-04 | — | — | WO | claimed |
| EP-4288057-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023230233-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2023-11-30 | — | — | WO | claimed |
| WO-2023220192-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | FOUNDATION MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| CN-116710141-A | Methods for preventing or treating antitumor agent-related diseases or conditions | 上海岸阔医药科技有限公司 | 2023-09-05 | — | — | CN | claimed |
| US-20230060581-A1 | METHOD OF TREATING PANCREATIC CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2023-03-02 | — | — | US | claimed |
| EP-4103286-A1 | METHOD OF TREATING PANCREATIC CANCER | Cedars-Sinai Medical Center (US) | 2022-12-21 | — | — | EP | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2022143628-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | 上海岸阔医药科技有限公司 | 2022-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | DUSP6, SOS1, DUSP1 | MAP2K1 40/4885MAP2K2 41/4885SMC2 1649/4885 |
| US-20240400519-A1 | CRYSTAL FORMS A, B, C, D, E, F AND G OF SELUMETINIB SULFATE AND PREPARATION METHODS THEREOF | SELE, BRAF, RAF1 | MAP2K1 223/4885MAP2K2 237/4885SMC2 3407/4885 |
| US-12552751-B2 | Crystal forms A, B, C, D, E, F and G of selumetinib sulfate and preparation methods thereof | BRAF, SELE, RAF1 | MAP2K1 397/4885MAP2K2 411/4885SMC2 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.